Key result
An optimized U7 snRNA scaffold enabled 76% RNA editing in vitro from a single DNA construct per cell and 75% editing in a Hurler syndrome mouse brain after one systemic AAV injection.
Why the study?
ADAR-mediated therapeutic RNA base editing using antisense guide RNAs is challenged by limits of in vivo delivery.
An engineered U7 snRNA scaffold significantly enhances ADAR-mediated RNA base editing efficiency in vitro and in vivo, offering a promising universal framework for antisense RNA therapies.
Enhances endogenous ADAR RNA editing efficiency; leaves open therapeutic translation for genetic diseases.
Custom RNA base editing exploiting the human Adenosine Deaminase Acting on RNA (ADAR) enzyme may enable therapeutic gene editing without DNA damage or use of foreign proteins. ADAR’s adenosine-to-inosine (effectively A-to-G) deamination activity can be targeted to transcripts using an antisense guide RNA (gRNA), but efficacy is challenged by limits of in vivo delivery. Embedding gRNAs into a U7 small nuclear RNA (snRNA) framework greatly enhances RNA editing with endogenous ADAR, and a 750-plex single-cell mutagenesis screen further improved the framework. An optimized scaffold with a stronger synthetic U7 promoter enables 76% RNA editing in vitro from a single DNA construct per cell, and 75% editing in a Hurler syndrome mouse brain after one systemic AAV injection, surpassing circular gRNA approaches. The technology also improves published DMD exon-skipping designs 25-fold in differentiated myoblasts. Our engineered U7 framework represents a universal scaffold for ADAR-based RNA editing and other antisense RNA therapies. The human ADAR enzyme can deaminate additional transcripts for therapeutic A-to-G RNA base editing using an antisense guide RNA. Here, authors engineer a universal guide RNA scaffold from the U7 snRNA, boosting editing efficiency from minimal doses, especially in organs with limited AAV delivery.
No takes yet. Share an insight, caveat, or question.
Byrne et al. (2025) studied Hurler syndrome (preclinical model). Engineered U7 snRNA scaffold with ADAR guide RNAs vs. Original SmOPT U7 hairpin or alternative gRNA designs was evaluated on RNA editing efficiency. An optimized U7 snRNA scaffold enabled 76% RNA editing in vitro from a single DNA construct per cell and 75% editing in a Hurler syndrome mouse brain after one systemic AAV injection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: